New Wave Holdings Corp. announced that Dr. Richard Knowles has agreed to play a key role on the Psychedelic Research Advisory Board. His role will include guiding and conducting research that supports the Company's goal of development and commercialization of psychedelic compound derived neuropsychiatric treatments, introducing new psilocybin, ketamine, MDMA, and LSD research initiatives, assisting in the development of new IP and acting as a liaison to key industry players. The Advisory Board will evaluate the potential positive effects its medicinal mushroom formulations could have on individuals suffering from indications such as anxiety/depression and Post Traumatic Stress Disorder (PTSD), bereavement and emotional disturbances as well as stress and substance abuse disorders.